Jason Luke News Today

Immigrants. [applause] you must have the right you pay into Social Security. Millionaires this morning that power ball jackpot just hit a new record. Swelling to 625 million. This is my town na na na na na this is my town brian if you live here its your town. Steve headliner right there iv i say they cant afford to live in my town. Jedediah we senator rick scott coming up to talk about just that. Steve indeed, he has written an oped for the wall street journal talking about how when he was the g...

The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.

Medical professionals explore CSCC and BCC treatment in high-risk, immunocompromised patients—specifically in the setting of organ transplantation.

Experts explore the socioeconomic impact of CSCC and BCC, and which late-stage patients will derive the greatest benefit from hedgehog inhibitors, immunotherapies, and other emerging treatments.

Experts discuss optimal utilization of CSCC and BCC staging systems and risk stratification to guide treatment decisions and the appropriate timing for active surveillance vs intervention.

The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC.

Key opinion leaders emphasize the role of coordinated care between dermatologists and oncologists in monitoring and managing adverse events related to immunotherapy in CSCC and BCC.

Dr Pisano shares insights on expanding dermatologists' comfort with immunotherapy through collaborative learning and collective expertise.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.